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Abstract. DNA methylation status in the CpG sites of pro-
moter regions in cancer-related genes, such as PTCH, has
traditionally been investigated using either dye-terminator
sequencing or methylation-specific PCR. We aimed to study
the PTCH gene promoter methylation in gynecological
cancers, with a method that gives a quantitative measure of
the methylation status of the promoter region of the studied
gene, and for this purpose, we designed novel Pyrosequencing-
based assays. Bisulfite-treated genomic DNA (bsDNA)
was amplified by standard PCR and applied to novel Pyro-
sequencing® assays, in order to measure the methylated fraction
(%) at each CpG site of the PTCH gene promoter. We analyzed
22 squamous cell cervical cancer tissue specimens (11
with good and 11 with poor outcomes after radiotherapy)
and 5 ovarian cancer tissue specimens matched with 5 normal
ovarian tissue specimens. Six optimized PCR protocols which
generated 8 Pyrosequencing assays covering 63 CpG sites in
the promoter regions 1 and 2 as well as the previously unana-
lyzed promoter region 3 in the PTCH gene were developed.
The 27 tumor tissue specimens and 5 normal tissues did
not show any methylation within any of the 63 CpG sites.
Our data suggest that methylation of the PTCH promoter is
not a high-prevalence feature of squamous cell cervical cancer
or ovarian cancer, but Pyrosequencing assays are a good
method for studying promoter methylation.
Introduction
The Patched gene (PTCH) is involved in the Hedgehog/Patched
signaling pathway and is known to play a role in mammalian
development and in regulation of stem cell renewal in adult
tissue (1). PTCH is a major pathway receptor localized to the
plasma membrane that moves to the endocytic vesicles upon
ligand binding (2,3), where the ligand could be either Sonic
(SHH), Indian (IHH) or Desert Hedgehog (DHH). PTCH
associates with the Smoothened protein (SMO) and inhibits
downstream targets such as PTCH, GLI1, HIP and TGF-ß (4)
in the absence of ligand. PTCH activity is repressed and
SMO is activated if SHH is present. This activity leads to the
translocation of the GLI protein to the nucleus and transcription
of downstream targets (5). 
Alterations in this pathway such as phenotypical changes
of the proteins involved because of mutations of the genes
(2,6), or dysregulation of the genes because of aberrant
methylation patterns of their promoter regions (7,8), can alter
carcinogenic transformation. 
PTCH is expressed in the adult human kidney, liver, lung,
brain, heart, placenta, skeletal muscle and pancreas (9). It has
been suggested that the PTCH gene has tumor-suppressor
function because it appears to be involved in the development
of several cancers such as ovarian dermoids, fibromas (7),
medulloblastoma (10), acute myeloid leukemia (11), uterine
cervical carcinoma (12), breast cancer (8), sporadic basal cell
carcinomas (13) and nevoid basal cell carcinoma (2). 
Epigenetic regulation, through methylation or demethy-
lation of CpG sites in promoter regions of cancer-related
genes by methyltransferases (14), plays an important role in
the pathogenesis of cancer (15). This mode of regulation can
be considered activating or silencing depending upon action.
PTCH has several alternative splicing sites (a, b, c, d and e)
starting from exon 1 (16,17). The most studied of these
regions, in relevance to epigenetic changes and regulatory
effects of the protein (7,8,12), contains the N-terminus encoded
by exon 1B (16,18). This particular variant is known to have
full inhibitory activity on SMO (18). Recent data suggest an
enhanced expression of the PTCH protein in squamous cell
carcinoma of uterine cervix and its precursor lesions (12). To
link this finding to possible changes in methylation status of
the promoter regions of PTCH, in response to ovarian cancer
development, is an overarching goal of our current PTCH
studies using dye-terminator sequencing. Recent findings
provide evidence of hypermethylation within the 1600-bp
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long PTCH gene promoter (7), which was divided into four
large overlapping contigs. Results were generated from regions
1, 2 and 4; however, region 3 was found to be unfeasible to
amplify (7). Dye-terminator sequencing generates a qualitative
assay output (presence or absence of methylation); therefore, it
is considered limited. This methodology is also generally
considered more labor intensive and more costly than other
DNA methylation analysis techniques.
Our goal in the present study was to dissect the promoter
region of the PTCH gene into a larger number of short
amplicons, in order to investigate the methylation status of
the CpG sites in region 3 that have not yet been studied. In
addition, we aimed to quantitatively determine the methylated
fraction of the remainder of the CpG sites in the promoter
region of the PTCH gene (Fig. 1). Therefore, we designed
new bisulfite-specific PCR (bs PCR) primers and new Pyro-
sequencing assays to quantify the methylated fraction of
63 CpG sites contained within the promoter region of the
PTCH gene. The assays were applied to a clinical sample of
cervical cancer tissues, selected from patients with poor or
good prognosis respectively, and to a sample of ovarian
cancer tissues with matching normal ovarian tissue controls.
Materials and methods
Subjects. EDTA blood plasma samples from our routine
laboratory were de-identified and used to optimize methods to
study the methylation status of selected CpG sites in exon 1b
in the promoter region of the PTCH gene. According to
Swedish Research Ethics Law on anonymized samples for
method development purposes, informed consent was waived
for these samples. The novel methods were subsequently
used in two clinical studies: a) 22 squamous cell cervical
cancer tissue specimens obtained before start of primary
radiotherapy of which 11 were from women with a poor
prognosis (recurrence of cervical cancer after radiotherapy)
and the other 11 from women with a good prognosis (no
recurrence of cervical cancer after radiotherapy). The two
groups were 100% matched for tumor stage. The Regional
Ethics Committee in Uppsala approved the Swedish part of
the study (Act No. 2008/089, 25th june 2008, Uppsala,
Sweden); b) 5 de-identified ovarian tumour tissue specimens
and 5 normal ovarian tissue specimens from the same patients
(kindly provided by Dr S. Oreskovic, Zagreb University
Hospital). 
The Ethics Committee of the University Hospital Centre
Zagreb, Department of Gynaecology and Obstetrics and
School of Medicine University of Zagreb on March 1st, 2006
gave statement on approved protocols for genetic research
on clinical samples from Department of Gynecology and
Obstetrics (Act No. 021-1/49-2006, Zagreb, Petrova 13). 
DNA isolation and bisulfite treatment. Genomic DNA (gDNA)
was extracted in three different ways. Either from 200 μl
whole EDTA blood using a BioRobot EZ1 (Qiagen Inc.,
Valencia, CA, USA) with the QIAamp EZ1 DNA blood 200 μl
kit according to the manufacturer's instruction (Qiagen),
otherwise from squamous cell cervical cancer tissue pieces
using the QIAamp DNA Mini Kit (Qiagen) or from ovarian
cancer tissue pieces using standard phenol-chloroform method.
In the latter method, all samples were first digested in
buffer (0.9% Tween-20, 0.9% Triton X-100, 5 mmol/l
EDTA, 2 mmol/l DTT, 10 mmol/l TrisHCl pH 7.5) and
proteinase K (20 μg/ml) overnight at 55˚C.
Approximately 1000 ng freshly extracted DNA was used
for the bisulfite treatment. The bisulfite treatment was
performed with the EZ DNA Methylation kit according to the
manufacturer's instructions (Zymo Research, Orange, CA,
USA); however, the incubation time was shortened to 10 h
if the DNA originated from tissue and not from blood. In
summary, DNA was diluted with M-Dilution buffer and
incubated for 15 min at 37˚C. CT conversion reagent was
added to the DNA samples from the previous step and
incubated again at 50˚C for 16 h (10 h if the DNA originated
from tissue). Finally, the samples were incubated on ice for
10 min and then M-Binding buffer was added. The samples
were centrifuged and then washed with M-Wash buffer. The
bsDNA was eluted in 10 μl M-Elution buffer and then diluted
5 times with TE buffer (10 mmol/l Tris-HCl, 0.05 mmol/l
EDTA, pH 7.5).
bs PCR. PCR primers for Pyrosequencing were designed
using Methprimer (http://www.urogene.org/methprimer/
index1.html). Primer sequences can be found in Table I.
The objective of the PTCH-gene-PCR primer design was
to amplify the same area and same CpG sites as previously
studied by Cretnik et al (7). We chose to shorten the amplicons
to be able to perform Pyrosequencing analysis of the CpG
sites, a technique where ~150-200 bp is the optimal amplicon
length (19). The PCR primers would also be uniquely
designed and devoid of CpG sites in primer-binding areas
such that amplification will always take place independent of
methylation status. This is also known as bisulfite-specific
PCR (bs PCR). We utilized the same numbering scheme of
CpG sites as reported by Cretnik et al (7) and as shown in
Table I and Fig. 1.
PCR was performed using an Eppendorf Mastercycler
(Eppendorf-Netheler-Hinz GmbH, Hamburg, Germany) and
the HotStarTaq DNA polymerase Kit (Qiagen); we used 30 or
60 μl volume reactions depending on the number of amplicons
required to analyze in the Pyrosequencer (PSQ 96MA system,
Biotage AB). Each reaction contained 0.4 μmol/l of each
primer, 1.25 U of Taq polymerase, 1.5 mmol/l MgCl2 and
0.2 mmol/l each of dGTP, dATP, dTTP and dCTP. Five μl of
the diluted bisulfite-treated gDNA served as the PCR template.
The PCR program consisted of an initial polymerase activation
step at 95˚C for 15 min followed by 53 cycles of denaturation
at 94˚C for 30 sec, primer annealing at 48-57˚C for 30 sec
and extension at 72˚C for 1 min. A final extension step at
72˚C for 7 min finalized the program. The PCR primers,
annealing temperatures and amplicon sizes for Pyrosequencing
are shown in Table I. 
Pyrosequencing. To quantify site-specific methylation, PCR
products from the bisulfite-treated genomic DNA samples
were analyzed with Pyrosequencing technology; the sequence
primers are summarized in Table I. The post-PCR (see above)
samples were prepared with the Vacuum Prep Workstation
(Biotage AB, Uppsala, Sweden) according to the following
protocol summary: 30 μl of the amplicon, 3 μl Streptavidin
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Sepharose HP Beads (Amersham Biosciences, Uppsala,
Sweden), 37 μl binding buffer (10 mmol/l Tris-HCl, 2 M NaCl,
1 mmol/l EDTA, 0.1% Tween-20, Milli-Q (18.2 Mø x cm)
water, pH 7.6) and 15 μl Milli-Q water were mixed and used
in the Vacuum Prep workstation. The biotinylated amplicons
were immobilized onto the Streptavidin sepharose beads and
then passed through one denaturation step and two washing
steps using the Vacuum Prep Workstation. The first step was
70% ethanol, the second 0.2 mol/l NaOH (denaturation step)
and the third was washing buffer (10 mmol/l Tris-Acetate,
Milli-Q water). The amplicons were transferred to a plate
containing sequencing primer (0.4 μmol/l) in 40 μl annealing
buffer (20 mmol/l Tris-acetate, 2 mmol/l magnesium acetate,
pH 7.6). The sequencing primer was annealed to the template
at 80˚C for 2 min. Pyrosequencing was performed using the
PSQ96 SNP Reagent Kit and the PSQ 96MA system (Biotage
AB). Pyrograms showing the nucleotide addition order can
be seen in Figs. 2-7. Pyro Q-CpG™ Software v. 1.0.9 was
used to determine the optimal order of nucleotide addition,
when designing the assays. The software also automatically
analyzed the methylation results. The % methylated fraction
(C/T ratio) is displayed in a small colored box just above
each CpG site in the analyzed sequence (Figs. 2-7). Each site
is analyzed as a C/T-polymorphism where a 100% C-reading
denotes a fully methylated C in the original gDNA sample
and a 100% T-reading denotes that this C was unmethylated
in the gDNA. Intermediate C/T percentages denote partial
methylation at the level of the sample.
Results
Our goal was to develop quantitative methods to measure the
methylated fraction of the CpG sites in the promoter region
of the PTCH gene without resorting to ‘methylation specific’
PCR. In addition, we specifically wanted to develop methods
to investigate the unstudied region three of the PTCH promoter
[Fig. 1 by Cretnik et al (7)]. We designed six new, shorter,
amplicons that were all successfully amplified using conven-
tional PCR with bisulfite treated gDNA as template (Table I). 
We also created eight Pyrosequencing assays (Table II)
that quantitatively analyzed 63 CpG sites (Figs. 2-7) in
regions 1 (Fig. 1, lines 1-6 in ref. 7) and 2 (Fig. 1, lines 6-10
in ref. 7), which have been previously studied by another
technique (7), and in addition we covered region 3 (Fig. 1,
lines 9-15 in ref. 7) that had been previously unfeasible to
study using dye-terminator sequencing (7). Table II displays
the length of the PCR amplicons, how many CpG sites they
cover and which of these are analyzed in our Pyrosequencing
assays. Amplicons 4 and 7 are analyzed using two different
Pyrosequencing assays each, whereas the others are covered
using one assay each. The amplicon 7 assay includes 25 CpG
sites, of which 19 are unique, while six of the analyzed CpG
sites overlap with the last six CpG sites covered by the
amplicon 6 assay, providing a useful internal check of the
validity of results. In 96 steps, the Pyrosequencing assay,
Amp6-Py1, analyses 16 CpG sites, which is rather unique, not
only for this method, but also for methylation analysis in
general (Fig. 6). 
All the eight assays were applied to two clinical study
groups comprising a total of 32 tissue samples. One sample
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consisted of 22 squamous cell cervical cancer tissue specimens,
from two groups of women: 11 with a poor prognosis (had
recurrence of cervical cancer after primary radiotherapy)
and 11 from women with a good prognosis (no recurrence
of cervical cancer after radiotherapy). The other comprised
five ovarian cancer tissues and five normal ovarian tissue
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Figure 1. DNA sequence of the analyzed region of the PTCH promoter. The sequence here is shown after bisulfite conversion in which hypothetically all non-
CpG sites cytosines are replaced with thymines, whereas cytosines within the CpG sites remain as cytosines. The forward and reverse primers (marked by
arrows) indicate the analyzed regions. The shaded boxes mark all the 164 CpG sites counted from the first (no. 1) in the figure to the last (no. 164) spread
throughout the ~1600-bp long promoter. Gli-binding sites are marked with circles and ATG is in a square.
Table II. Amplicon sizes, number of CpG sites in the templates, designation of Pyrosequencing assays and number of CpG
sites analyzed for 6 different amplicons of the PTCH gene.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
PCR Amplicon No. of CpG sites Designation of the No. of CpG sites analyzed 
amplicon length (bp) in the template Pyrosequencing assays by the assay
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Amp2 163 4 Amp2-Py1 4
Amp3 187 9 Amp3-Py1 7
Amp4 188 11 Amp4-Py1 4
Amp4-Py2 7
Amp5 117 8 Amp5-Py1 6
Amp6 274 38 Amp6-Py1 16
Amp7 198 25 Amp7-Py1 13
Amp7-Py2 6
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
685-692.qxd  26/1/2011  09:10 Ì  ™ÂÏ›‰·688
samples, matched from each patient. None of these 32 tissue
samples showed any signs of methylation in any of the eight
Pyrosequencing assays.
Discussion
We optimized our PCR and Pyrosequencing protocols (Table I
and Figs. 2-7) with gDNA originating from human leukocytes.
This is a cell type that turned out to be unmethylated, as
expected, on all CpG sites studied in the PTCH promoter
(Figs. 2-7). Unexpectedly, none of the 22 squamous cell
cervical cancer or 5 ovarian cancer tissues tested, showed
methylated CpG sites in any of the eight PTCH assays.
Therefore, PTCH promoter methylation is probably not a
high-prevalence event in squamous cell cervical cancer or
ovarian cancer. This is not a surprising finding, since it has
been shown that cervical cancer samples usually show
increased expression of PTCH protein (12), and the same is
true for ovarian cancer (20), although LOH of the PTCH region
has been associated with some types of ovarian cancer (21).
Extended applications of these newly-developed assays to
larger series of cancer tissues from other cell types will be
needed to clarify the extent and role of PTCH promoter
methylation in other human cancers.
The current and perhaps most popular methodology to
study DNA methylation, ‘methylation specific’ PCR (often
featured in microarrays), has the limitation of only assaying
the methylation status of a few CpG sites that interfere with
PCR-primer binding. This technique only gives a qualitative
indication if the sites are methylated or not; like all ‘allele
specific’ PCR methods, the judgment of the presence or
absence of a band on an agarose gel is largely a matter of the
combination of the number of PCR optimization experiments
made and subjective analysis of gel electrophoresis bands.
We believe that these drawbacks are a real cause of concern,
which may have stalled progress in the understanding of the
role of DNA methylation in clinical cancer research. Compared
to ‘methylation specific’ PCR, Pyrosequencing technology
and Pyro Q-CpG Software v. 1.0.9 automatically generate a
quantitative measure in percent methylation for each CpG
site in the studied sequence. This methodology allows the
detection of partially methylated CpG sites; therefore, yielding
a more accurate picture of how the methylation is distributed
throughout the promoter region than the qualitative assays.
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Figure 2. Typical pyrogram showing the sequence analyzed in Amp 2 in the PTCH gene by the Amp 2-Py1 assay. The G base added at nt 20 (lighter grey
background) is a negative control to ascertain good bisulfite conversion of the sample. 
Figure 3. Typical pyrogram showing the sequence analyzed in Amp 3 in the PTCH gene by the Amp 3-Py1 assay.
685-692.qxd  26/1/2011  09:10 Ì  ™ÂÏ›‰·689
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Figure 4. Typical pyrograms showing the sequences analyzed in Amp 4 in the PTCH gene. This amplicon was divided into two different Pyrosequencing
assays, Amp4-Py1 (upper panel) and Amp4-Py2 (lower panel). 
Figure 5. Typical pyrogram showing the sequence analyzed in Amp 5 in the PTCH gene by the Amp 5-Py1 assay.
Figure 6. Typical pyrogram showing the sequence analyzed in Amp 6 in the PTCH gene by the Amp 6-Py1 assay.
685-692.qxd  26/1/2011  09:10 Ì  ™ÂÏ›‰·690
Analysis of CpG sites in the PTCH gene is unusually
challenging owing to method development aspects, but only
36 CpG sites in the PTCH promoter remained uncovered by
our assays designed for regions 1 and 2, recently studied by
conventional DNA sequencing (7) and region 3, previously
considered unfeasible to amplify. Pyrosequencing assays
could not be developed for region 4 due to the extensive
amount of CpG sites, including 63 sites densely grouped
within a 456-bp region (Fig. 1, lines 15-20 in ref. 7): there
were no stretches of unique, CpG-free sequences where PCR
primers could bind; therefore, it could not be split into smaller
amplicons. We also attempted to analyze this 456 bp amplicon
directly by Pyrosequencing, but as expected, it turned out
to be too long to analyze; optimal amplicon length for this
technique is around 150-200 bp. Therefore, CpGs in that
region still await to be quantified by other means.
In conclusion, we developed eight Pyrosequencing assays
to quantify the methylation of promoter regions 1, 2 and
the previously unanalyzed region 3 of the PTCH gene. Our
data suggest that methylation of the PTCH promoter is not a
high-prevalence feature of squamous cell cervical cancer
or ovarian cancer. Clinical applications of the novel DNA
methylation assays, in order to characterize the conditions
associated with PTCH promoter methylation in various
cancer forms, will be the object of our further studies. 
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